TickerStat.comEloxx Pharmaceuticals annual operating cash flow
2010
2011
2012
2013
2014
2015
2015
2016
2016
2017
2017
2018
2019
2020
2021
2022
2023
2024
2025
Eloxx Pharmaceuticals Operating Cash Flow Growth & History (ELOX)
Eloxx Pharmaceuticals's operating cash flow was −$6.3M for fiscal 2025.
View full Eloxx Pharmaceuticals company overviewEloxx Pharmaceuticals annual operating cash flow history
| Fiscal year | Period ended | Operating cash flow | Change | Growth |
|---|---|---|---|---|
| 2025 | 2025-12-31 | −$6.3M | −$1.6M | — |
| 2024 | 2024-12-31 | −$4.7M | $9.6M | — |
| 2023 | 2023-12-31 | −$14.3M | $17.5M | — |
| 2022 | 2022-12-31 | −$31.8M | $3.2M | — |
| 2021 | 2021-12-31 | −$35.0M | −$6.8M | — |
| 2020 | 2020-12-31 | −$28.2M | $11.2M | — |
| 2019 | 2019-12-31 | −$39.4M | −$8.0M | — |
| 2018 | 2018-12-31 | −$31.4M | −$15.4M | — |
| 2017 · Dec 31 | 2017-12-31 | −$15.9M | −$7.1M | — |
| 2017 · Jun 30 | 2017-06-30 | −$1.9M | $1.8M | — |
| 2016 · Dec 31 | 2016-12-31 | −$8.8M | −$3.1M | — |
| 2016 · Jun 30 | 2016-06-30 | −$3.7M | $3.7M | — |
| 2015 · Dec 31 | 2015-12-31 | −$5.7M | — | — |
| 2015 · Jun 30 | 2015-06-30 | −$7.3M | −$2.5M | — |
| 2014 | 2014-06-30 | −$4.9M | −$965,507 | — |
| 2013 | 2013-06-30 | −$3.9M | $483,423 | — |
| 2012 | 2012-06-30 | −$4.4M | $1.0M | — |
| 2011 | 2011-06-30 | −$5.4M | −$648,313 | — |
| 2010 | 2010-06-30 | −$4.7M | — | — |
Eloxx Pharmaceuticals quarterly operating cash flow
Q1.11
Q2.11
Q3.11
Q4.11
Q1.12
Q2.12
Q3.12
Q4.12
Q1.13
Q2.13
Q3.13
Q4.13
Q1.14
Q2.14
Q3.14
Q4.14
Q1.15
Q2.15
Q3.15
Q4.15
Q1.16
Q4.15
Q1.16
Q4.16
Q1.17
Q4.16
Q1.17
Q4.17
Q1.18
Q4.17
Q1.18
Q2.18
Q3.18
Q4.18
Q1.19
Q2.19
Q3.19
Q4.19
Q1.20
Q2.20
Q3.20
Q4.20
Q1.21
Q2.21
Q3.21
Q4.21
Q1.22
Q2.22
Q3.22
Q4.22
Q1.23
Q2.23
Q3.23
Q4.23
Q1.25
Q2.25
Q1.26
Q2.26
| Fiscal quarter | Period ended | Operating cash flow | Change | YoY change |
|---|---|---|---|---|
| Q2 2026 | 2026-06-30 | −$4.8M | −$3.0M | — |
| Q1 2026 | 2026-03-31 | −$5.5M | −$6.7M | — |
| Q2 2025 | 2025-06-30 | −$1.8M | — | — |
| Q1 2025 | 2025-03-31 | $1.2M | — | — |
| Q4 2023 | 2023-12-31 | −$2.0M | $3.6M | — |
| Q3 2023 | 2023-09-30 | −$3.5M | $3.5M | — |
| Q2 2023 | 2023-06-30 | −$2.1M | $7.7M | — |
| Q1 2023 | 2023-03-31 | −$6.8M | $2.7M | — |
| Q4 2022 | 2022-12-31 | −$5.7M | $4.3M | — |
| Q3 2022 | 2022-09-30 | −$6.9M | $642,000 | — |
| Q2 2022 | 2022-06-30 | −$9.7M | $50,000 | — |
| Q1 2022 | 2022-03-31 | −$9.5M | −$1.8M | — |
| Q4 2021 | 2021-12-31 | −$9.9M | −$5.3M | — |
| Q3 2021 | 2021-09-30 | −$7.6M | −$2.3M | — |
| Q2 2021 | 2021-06-30 | −$9.8M | −$3.5M | — |
| Q1 2021 | 2021-03-31 | −$7.7M | $4.2M | — |
| Q4 2020 | 2020-12-31 | −$4.7M | $4.6M | — |
| Q3 2020 | 2020-09-30 | −$5.3M | $6.1M | — |
| Q2 2020 | 2020-06-30 | −$6.3M | $3.3M | — |
| Q1 2020 | 2020-03-31 | −$11.9M | −$2.7M | — |
| Q4 2019 | 2019-12-31 | −$9.3M | −$197,000 | — |
| Q3 2019 | 2019-09-30 | −$11.3M | −$3.2M | — |
| Q2 2019 | 2019-06-30 | −$9.6M | −$1.1M | — |
| Q1 2019 | 2019-03-31 | −$9.2M | −$3.5M | — |
| Q4 2018 | 2018-12-31 | −$9.1M | −$15.4M | — |
| Q3 2018 | 2018-09-30 | −$8.1M | −$7.5M | — |
| Q2 2018 | 2018-06-30 | −$8.5M | −$5.3M | — |
| Q1 2018 · Mar 31 | 2018-03-31 | −$5.7M | −$3.0M | — |
| Q4 2017 | 2017-12-31 | $6.3M | $6.7M | — |
| Q1 2018 · Sep 30 | 2017-09-30 | −$575,324 | −$1,580 | — |
| Q4 2017 · Jun 30 | 2017-06-30 | −$3.2M | −$2.5M | — |
| Q1 2017 · Mar 31 | 2017-03-31 | −$2.7M | −$1.9M | — |
| Q4 2016 | 2016-12-31 | −$437,871 | $550,425 | — |
| Q1 2017 · Sep 30 | 2016-09-30 | −$573,744 | $558,410 | — |
| Q4 2016 | 2016-06-30 | −$714,786 | $1.7M | — |
| Q1 2016 · Mar 31 | 2016-03-31 | −$840,979 | $610,538 | — |
| Q4 2015 | 2015-12-31 | −$988,296 | $544,811 | — |
| Q1 2016 · Sep 30 | 2015-09-30 | −$1.1M | $807,243 | — |
| Q4 2015 | 2015-06-30 | −$2.4M | −$1.2M | — |
| Q3 2015 | 2015-03-31 | −$1.5M | $105,952 | — |
| Q2 2015 | 2014-12-31 | −$1.5M | −$111,168 | — |
| Q1 2015 | 2014-09-30 | −$1.9M | −$1.3M | — |
| Q4 2014 | 2014-06-30 | −$1.2M | −$271,932 | — |
| Q3 2014 | 2014-03-31 | −$1.6M | $196,960 | — |
| Q2 2014 | 2013-12-31 | −$1.4M | −$856,524 | — |
| Q1 2014 | 2013-09-30 | −$670,465 | −$34,011 | — |
| Q4 2013 | 2013-06-30 | −$946,328 | $161,814 | — |
| Q3 2013 | 2013-03-31 | −$1.8M | −$774,407 | — |
| Q2 2013 | 2012-12-31 | −$565,415 | $642,232 | — |
| Q1 2013 | 2012-09-30 | −$636,454 | $453,784 | — |
| Q4 2012 | 2012-06-30 | −$1.1M | −$84,596 | — |
| Q3 2012 | 2012-03-31 | −$980,022 | $310,080 | — |
| Q2 2012 | 2011-12-31 | −$1.2M | $264,528 | — |
| Q1 2012 | 2011-09-30 | −$1.1M | $515,381 | — |
| Q4 2011 | 2011-06-30 | −$1.0M | — | — |
| Q3 2011 | 2011-03-31 | −$1.3M | — | — |
| Q2 2011 | 2010-12-31 | −$1.5M | — | — |
| Q1 2011 | 2010-09-30 | −$1.6M | — | — |
Eloxx Pharmaceuticals operating cash flow trends
Over the last five fiscal years, Eloxx Pharmaceuticals's operating cash flow increased from −$28.2M to −$6.3M, a change of $21.8M. The latest reported quarter, Q2 2026, shows −$4.8M.
About the metric
What operating cash flow means
Operating cash flow is the cash generated or used by a company’s core operations. It incorporates working-capital movements and other operating cash items, and it is the starting point for calculating free cash flow.
Calculation and source
SEC-reported operating cash flow
TickerStat standardizes net cash provided by or used in operating activities reported in company SEC filings. It is historical filing data before capital expenditures, financing activities, and investing activities. Fiscal periods can differ from calendar years, so exact period-end dates are included.
Review Eloxx Pharmaceuticals source filings ↗Community posts
Eloxx doses first patients in mid-stage Alport syndrome trial
Eloxx Pharmaceuticals ($ELOX) dosed the first two patients in its Phase 2b EXACT study of exaluren for Alport syndrome caused by nonsense mutations. The trial plans to enroll 24 patients with relevant mutations in the COL4A3, COL4A4 or COL4 ...